Sentences with phrase «stocks over growth»

I like the idea of Dividend stocks over growth.

HML in the Fama and French context measures the historic excess returns of value stocks over growth stocks, which break the traditional CAPM model.

Favor large caps over small caps and value stocks over growth stocks.

Chad Morganlander, portfolio manager with Washington Crossing Advisors, recently went overweight value stocks over growth stocks.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Sales were flat in North America, compared with a 38 percent growth in the Asia - Pacific region, but that was enough to knock 5 percent off the stock which has gained more than two - thirds in value over the past year.

BAML also cites corporate earnings growth as a tailwind to stock prices, though it notes that global purchasing manager data is «rolling over,» signaling a slowdown to come.

Given the earnings growth that you can get just from tax rate reduction, that helps the valuations for some of these stocks over which there's been some debate about overvaluation.

Still, he expects good share - price growth over the next few years, and if Europe's economic fortunes improve, then investors could see stocks soar.

Conversely, Southwest saw its stock tumble 18 % over one stretch of 2016 following its decision to continue expanding while other airlines were restraining growth.

The bearish sentiment in Asia followed a softer lead from Wall Street, which has led a global equities rally over the past year thanks to strong world growth fueling higher corporate earnings and stock valuations.

The stock has fallen 8 percent in the past month on concern over slowing smartphone growth.

Tom Wynn, director of affluent research at Spectrem, provided several factors for the increased confidence: the steady improvement in job growth, the steady increase in the major stock market indices since the spring, and a decrease in political ambiguity with the election season over, which has an effect on at least some people's outlook.

According to Panera, the growth in the MyPanera program has allowed the company to significantly increase the efficiency of its marketing, and perhaps not coincidentally, over the past year, the company's stock price has increased almost 30 percent.

New York, Dec 11 - U.S. stocks edged higher in intraday trading on Monday after worries receded over an explosion in New York's busy Port Authority commuter hub, while stocks rose around the world on continued solid global economic growth indicators.

The extra growth you get on your stock market portfolio, compounded over 30 years, will more than make up for what you lose on rental inflation.

Skeptics see a company whose earnings - per - share growth, which has averaged 30 % annually over the past five years, is bound to slow down, which makes it tough to justify paying 23 times estimated 2017 earnings for the stock.

Because PE is a measure of earnings over time, you can think of it as representing the number of years required to pay back a stock's purchase price (ignoring inflation, earnings growth and the time value of money).

The stock is trading at the high end of its historical range, but its «industry leading earnings and free cash flow growth» make up for that higher multiple, he said The stock is currently trading at $ 191 a share, but Hansen said it will hit $ 220 over the next 12 - months.

The stock has climbed by 50 % over the last 12 months — partly due to the 41 % year - over-year earnings per share growth it saw in Q3 2013 — but Campbell thinks it still has room to run.

«Fundamentals are still positive, there is strong economic growth and strong earnings growth - those will help stocks move higher over time,» said Kate Warne, investment strategist at Edward Jones in St. Louis.

We expect faster earnings growth outside the US in 2015 and, with lower valuations and a looser policy stance, we prefer «international» stocks over US stocks.

So if earnings growth has been so anemic, why have stocks continued to soar over the past few years — with the S&P 500 rising 29 % since September 2014?

Apple's stock has been in a slump since its last earnings report in July, and some analysts have said it's unlikely the company can maintain the rapid growth it enjoyed over the last year.

The market's price - to - earnings ratio (based on the latest 12 months reported results) raced higher in late 2017 and through January on growth - stock leadership and enthusiasm over tax - cut - juiced profit windfalls for companies.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

In addition, RTN appears to have a healthy, sustainable revenue growth rate of over 5 %, and the stock distributes a dividend of about 1.7 %.

At the point the growth began to slow, the multiple would contract, meaning that even if its earnings do grow 600 % in the next few years, if it becomes subject to the law of big numbers - that ever increasing amounts eventually forge their own anchor - the result would be a market capitalization substantially similar to today, leading to no increase in the stock price over a long period of time.

But anyone hoping for the kind of stock growth Shoppers enjoyed over the past decade — when its share price climbed from less than $ 18 to, at one point, over $ 55 — will be disappointed.

Right now with earnings growth very strong and the bond market already reflecting a fair amount of Fed tightening (pricing in 5 rate hikes over the coming 2 years), my sense is that the stock market is in OK shape to withstand some tightening of financial conditions and not unravel in the process.

Dividend investing is a small portion of my net worth (but growing) because I've always focused on growth stocks over dividend stocks to build my capital faster.

When the world's largest holding company posts its biggest stock decline in almost two decades and predicts no growth for 2018, there will inevitably be questions over whether the holding company model is irreparably broken.

The chart below shows that the Value stocks, as represented by the Russell 1000 Value Index, have underperformed growth stocks over the last ten years by 61 %.

This growth rate is the compound annual growth rate of cash dividends per common share of stock over the last 5 years.

Moreover, many industry experts attest that being added to the Dow may well herald the twilight of the stock's impressive growth run over the past several years.

The stock has risen over the past year as investors have generally rewarded the company for its earnings growth and other positive factors like the ones we have cited in this report.

There are a multitude of reasons as to why this occurs but it's a powerful enough force that many investors have done quite well for themselves over an investing lifetime by focusing on dividend stocks, specifically one of two strategies - dividend growth, which focuses on acquiring a diversified portfolio of companies that have raised their dividends at rates considerably above average and high dividend yield, which focuses on stocks that offer significantly above - average dividend yields as measured by the dividend rate compared to the stock market price.

Here's why I prefer investing in growth stocks over dividend stocks.

While stocks have a terminal value beyond a 10 - year period, the effects of interest rates and nominal growth on those projections largely cancel out because higher nominal GDP growth over a given 10 - year horizon is correlated with both higher interest rates and generally lower market valuations at the end of that period.

The company «s stock has declined about 35 percent over the past 12 months, and disappointing quarterly result in a forecast of zero revenue growth for 2018.

Long - term compensation, generally in the form of stock option grants under our Long - Term Incentive Compensation Plan (LTICP), to reward named executives for contributions to growth in stockholder value over the long term;

If a breakup of the company delivers the cost savings that Peltz believes and improves pre-tax margins to 17 % and spurs 8 % revenue growth for 15 years, the stock is worth over $ 90 / share.

While I personally prefer to invest in dividend growth stocks you should choose a strategy that you both understand and will remain committed to over the long - term.

The stock has dropped over 50 % in the past eight months, and even if the firm's growth slows dramatically and margins shrink, the stock's cheap valuation makes it a safe stock with high potential upside.

The r - squared value of 0.0006 in Figure 1 shows that EPS growth over the past five years explains less than one tenth of one percent of the difference in price between stocks in the S&P 500.

Strategic Growth is a risk - managed growth fund that is intended to accept exposure to U.S. stocks over the full market cycle, but with smaller periodic losses than a passive buy - and - hold appGrowth is a risk - managed growth fund that is intended to accept exposure to U.S. stocks over the full market cycle, but with smaller periodic losses than a passive buy - and - hold appgrowth fund that is intended to accept exposure to U.S. stocks over the full market cycle, but with smaller periodic losses than a passive buy - and - hold approach.

I just consider myself lucky that I happened onto the dividend growth investing strategy fairly early when I decided to start investing in stocks and then the FI blogging community which I've learned so much from here over the last year.

As a dividend growth investor, you can look at several metrics to evaluate the performance of a stock over the last months, years or even decades.

In a more optimistic scenario of 5 % compound annual NOPAT growth over the next decade, the stock is worth $ 100 / share today — a 54 % upside.

Upside reward potential is strong as the stock has to go over $ 82 / share to trade at a value that implies the company's profits will experience a 0 % decline, a no - growth scenario.